Biotech Values

[DewDiligence]

If AMRN wanted to increase its liquidity while waiting for the REDUCE-IT results, one would think there were better alternatives than the debt swap AMRN just engineered, which doesn’t ensure monetization. It might have been better to simply issue new common shares outright, possibly using a portion of the proceeds to buy back some of the old (steeply discounted) debt to reduce interest payments.